Impact of donor characteristics on prognosis for myelodysplastic syndromes after haplo-identical transplantation: a retrospective study
- VernacularTitle:供者特征对骨髓增生异常综合征患者单倍型移植预后的影响：一项回顾性队列研究
- Author:
Hong WANG
1
;
Xueqian LI
1
;
Qingyuan WANG
1
;
Jiaqian QI
1
;
Huiying QIU
1
;
Chengcheng FU
1
;
Xiaowen TANG
1
;
Miao MIAO
1
;
Ying WANG
1
;
Suning CHEN
1
;
Changgeng RUAN
1
;
Depei WU
1
;
Yue HAN
1
Author Information
- Publication Type:Journal Article
- Keywords: Haplo-identical donor transplantation; Donor selection; Myelodysplastic syndrome; Prognosis
- From: Chinese Journal of Hematology 2025;46(11):1026-1031
- CountryChina
- Language:Chinese
- Abstract: Objective:To evaluate the impact of donor characteristics on the prognosis of myelodysplastic syndrome (MDS) patients undergoing haplo-identical transplantation (HIDT) .Methods:A retrospective analysis of 203 MDS patients who received HIDT was conducted to evaluate how donor factors influenced transplant outcomes.Results:In MDS patients undergoing haploidentical transplantation, donors over 50 years were associated with higher EBV reactivation (2-year cumulative incidence 42.9% vs 22.0% for <50 years old; P=0.010). Female donors were linked to increased severe chronic GVHD compared with male donors (2-year incidence 11.9% vs 4.0% ; P=0.017). Additionally, 2-year overall survival (OS) was slightly lower with female donors than male donors (56.6% vs 69.7% ), but the difference was not statistically significant ( P=0.073). Donor-recipient blood type did not affect post-transplant OS or cumulative relapse rates. Donor-recipient kinship analysis revealed that child donors, compared to haploidentical sibling or parent donors, had lower rates of grade Ⅱ–Ⅳ acute GVHD (27.2% vs 45.7% vs 53.5%, P=0.007) and 2-year EBV reactivation (13.9% vs 29.3% vs 38.9%, P=0.001). For donors under 20 years, donor gender did not significantly affect 2-year OS ( P=0.913), relapse-free survival ( P=0.716), or 100-day incidence of grade Ⅱ–Ⅳ acute GVHD ( P=0.359) . Conclusion:For MDS patients undergoing HIDT, donors over 50 should be avoided. Male and child donors are preferred, while donor gender does not significantly affect outcomes if the donor is under 20 years old.
